Vertex to acquire Alpine Immune for $65/share; Q1 net loss $17.9M

ALPINE IMMUNE SCIENCES, INC.

Vertex acquires Alpine for $65 per share in cash; transaction unanimously approved, expected to close in Q2 2024.
Q1 net loss $17.9M ($0.28 per share) vs $13.3M loss in Q1 2023.
Cash and investments $362.4M as of March 31, 2024; sufficient to fund operations into 2026.
Collaboration revenue $7.0M, down from $9.4M; R&D expense up to $22.5M from $19.6M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ALPINE IMMUNE SCIENCES, INC. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, Alpine Immune Sciences, Inc. issued a press release reporting its financial results for the three months ended March 31, 2024.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001626199-24-000063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.